Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Business Roundup

July 23, 2007 | A version of this story appeared in Volume 85, Issue 30

Akzo Nobel's Organon business unit is teaming up with Dyax to discover and develop human therapeutic antibodies for the treatment of autoimmune diseases and cancer. For license fees, research funding, milestone payments, and royalties, Dyax will use its proprietary phage display technology to identify antibodies directed toward a promising target found at Organon's research center in Cambridge, Mass.

Penwest Pharmaceuticals has agreed to pay $7.5 million to license Edison Pharmaceuticals' drug EPI-A0001, a treatment of inherited mitochondrial respiratory chain diseases. Penwest plans to submit an Investigational New Drug Application for EPI-AOO1 to FDA in early 2008. The companies will also collaborate to discover and develop drugs to treat other mitochondrial diseases.

Evotec has doubled the capacity of its sterile active pharmaceutical ingredient (API) manufacturing facility in Glasgow, Scotland. The company says the project was undertaken in response to demand for liquid and lyophilized, or freeze-dried, APIs.

Roche Chairman and CEO Franz B. Humer, 61, is halving his job and will serve solely as chairman of the company as of the next annual meeting on March 4, 2008. He will be succeeded as CEO by Severin Schwan, 40, currently CEO of Roche Diagnostics. Humer has held the dual post since 2001; prior to that he was CEO, appointed in 1998.

Huntsman will host and operate an 89 million-gal-per-year biodiesel plant to be constructed by RBF Port Neches, an affiliate of private equity firm MatlinPatterson.

The earthquake measuring 6.8 on the Richter scale that hit Japan on the morning of Monday, July 16, caused little damage to the country's chemical industry. This tremor was centered in Niigata prefecture, a region where data from the Japan Chemical Industry Association show few chemical plants.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.